For example, a patient with metastatic NSCLC treated with pembrolizumab developed skin lesions containing infiltrating CD8+PD-1+ T-cells expressing the proliferation marker Ki-67 [9]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.